Title
Category
Credits
Event date
Cost
- Wilson Disease
- Genetics
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Due to Wilson disease myriad manifestations, its rarity, and its range of symptoms, differential diagnosis may be challenging, leading to delays in treatment. This Neuroscience Commentary reviews diagnostic acumen and the latest updates in the field.
- Alzheimer Disease
- Cognition
- Dementia
- Geriatric Psychiatry
- Neurology
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Among the most transformative Alzheimer Disease discoveries is the existence of biomarkers which can manifest decades before onset of disease-related dementia.
- Alzheimer Disease
- Cognition
- Dementia
- Geriatric Psychiatry
- Neurology
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Navigating the associated differential diagnosis in AD is essential as various causes of cognitive impairment require different treatment strategies.
- Cardiology
- Comorbidity
- Education
- Integrated Care
- Medical Conditions
- Pulmonary Disease
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
Pulmonary arterial hypertension requires risk stratification to develop goal-directed treatment plans, including combination therapy targeting multiple pathways.
- Tardive Dyskinesia
- 0.25 AMA PRA Category 1 Credit™
- 0.25 Participation
$0.00
In this Tweetorial learn the causes, signs and symptoms, assessments tools, and treatments for the medication-induced movement disorder tardive dyskinesia.
- Rett Syndrome
- Child and Adolescent Psychiatry
- Movement Disorders
- Neurology
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
Because of the multiple comorbidities associated with Rett syndrome, clinicians are advised to incorporate clinical guidelines that suggest implementing therapeutics with a multidisciplinary approach and with an eye toward new and emerging therapies.
- Rett Syndrome
- 0.25 AMA PRA Category 1 Credit™
- 0.25 Participation
$0.00
Because of the multiple comorbidities and symptoms associated with Rett syndrome, clinicians are advised to implement a multidisciplinary approach to disease management with an eye toward new and emerging therapies on the horizon.
- Depression
- Major Depressive Disorder
- Women’s Mental Health
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Pharmacology for MDD is limited by low efficacy, delayed response, and side effects. Research on the pathophysiology of the disease that includes the glutamatergic system and GABA signaling is ushering in a new era for rapidly acting antidepressants.
- Depression
- Major Depressive Disorder
- Women’s Mental Health
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
The new fast-acting antidepressants esketamine, an NMDA receptor antagonist, and positive allosteric modulators of GABAergic neurotransmission brexanolone and zuranolone have created an important and exciting paradigm shift in the treatment of depression.
- Renal Disease
- Cardiology
- 0.25 AMA PRA Category 1 Credit™
- 0.25 Participation
$0.00
Clinicians have a number of therapeutic agents to choose from when treating T2D at risk of CKD. However, it's important to know how to sequence these therapies in real-world practice.